155 related articles for article (PubMed ID: 35464999)
1. Efficacy, Safety, and Prognosis of Sequential Therapy with Tamoxifen and Letrozole versus Letrozole Monotherapy for Breast Carcinoma.
Lu X; Qian C
Comput Math Methods Med; 2022; 2022():1979254. PubMed ID: 35464999
[TBL] [Abstract][Full Text] [Related]
2. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Láng I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thürlimann B; ;
Lancet Oncol; 2011 Nov; 12(12):1101-8. PubMed ID: 22018631
[TBL] [Abstract][Full Text] [Related]
3. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).
Wasan KM; Goss PE; Pritchard PH; Shepherd L; Palmer MJ; Liu S; Tu D; Ingle JN; Heath M; Deangelis D; Perez EA
Ann Oncol; 2005 May; 16(5):707-15. PubMed ID: 15817595
[TBL] [Abstract][Full Text] [Related]
4. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
; Mouridsen H; Giobbie-Hurder A; Goldhirsch A; Thürlimann B; Paridaens R; Smith I; Mauriac L; Forbes J; Price KN; Regan MM; Gelber RD; Coates AS
N Engl J Med; 2009 Aug; 361(8):766-76. PubMed ID: 19692688
[TBL] [Abstract][Full Text] [Related]
5. Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study.
Wasan KM; Goss PE; Pritchard PH; Shepherd L; Tu D; Ingle JN
Breast Cancer Res Treat; 2012 Dec; 136(3):769-76. PubMed ID: 23089983
[TBL] [Abstract][Full Text] [Related]
6. Update of the BIG 1-98 Trial: where do we stand?
Joerger M; Thürlimann B
Breast; 2009 Oct; 18 Suppl 3():S78-82. PubMed ID: 19914548
[TBL] [Abstract][Full Text] [Related]
7. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
[TBL] [Abstract][Full Text] [Related]
8. A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients.
Aphinives P; Vachirodom D; Thanapaisal C; Rangsrikajee D; Somintara O
Breast Cancer (Dove Med Press); 2015; 7():37-41. PubMed ID: 25653555
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
Ingle JN; Suman VJ; Johnson PA; Krook JE; Mailliard JA; Wheeler RH; Loprinzi CL; Perez EA; Jordan VC; Dowsett M
Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
[TBL] [Abstract][Full Text] [Related]
10. Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
Rabaglio M; Sun Z; Maibach R; Giobbie-Hurder A; Ejlertsen B; Harvey VJ; Neven P; Láng I; Bonnefoi H; Wardley A; Ruepp B; Castiglione M; Coates AS; Gelber RD; Goldhirsch A; Colleoni M; Thürlimann B; Regan MM
Breast Cancer Res Treat; 2021 Feb; 185(3):697-707. PubMed ID: 33159633
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
Ruhstaller T; Giobbie-Hurder A; Colleoni M; Jensen MB; Ejlertsen B; de Azambuja E; Neven P; Láng I; Jakobsen EH; Gladieff L; Bonnefoi H; Harvey VJ; Spazzapan S; Tondini C; Del Mastro L; Veyret C; Simoncini E; Gianni L; Rochlitz C; Kralidis E; Zaman K; Jassem J; Piccart-Gebhart M; Di Leo A; Gelber RD; Coates AS; Goldhirsch A; Thürlimann B; Regan MM;
J Clin Oncol; 2019 Jan; 37(2):105-114. PubMed ID: 30475668
[TBL] [Abstract][Full Text] [Related]
12. Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis.
He T; Li X; Li J; Wang Z; Fan Y; Li X; Fu Z; Wu Y; Lv Q; Luo T; Zhong X; Chen J
Front Oncol; 2021; 11():670897. PubMed ID: 35111662
[TBL] [Abstract][Full Text] [Related]
13. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.
Del Mastro L; Mansutti M; Bisagni G; Ponzone R; Durando A; Amaducci L; Campadelli E; Cognetti F; Frassoldati A; Michelotti A; Mura S; Urracci Y; Sanna G; Gori S; De Placido S; Garrone O; Fabi A; Barone C; Tamberi S; Bighin C; Puglisi F; Moretti G; Arpino G; Ballestrero A; Poggio F; Lambertini M; Montemurro F; Bruzzi P;
Lancet Oncol; 2021 Oct; 22(10):1458-1467. PubMed ID: 34543613
[TBL] [Abstract][Full Text] [Related]
14. Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.
Giobbie-Hurder A; Price KN; Gelber RD; ;
Clin Trials; 2009 Jun; 6(3):272-87. PubMed ID: 19528136
[TBL] [Abstract][Full Text] [Related]
15. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
16. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
18. Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole.
Bell LN; Nguyen AT; Li L; Desta Z; Henry NL; Hayes DF; Wolff AC; Stearns V; Storniolo AM; Flockhart DA;
J Clin Pharmacol; 2012 Dec; 52(12):1852-60. PubMed ID: 22174434
[TBL] [Abstract][Full Text] [Related]
19. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.
Kusama M; Miyauchi K; Aoyama H; Sano M; Kimura M; Mitsuyama S; Komaki K; Doihara H
Breast Cancer Res Treat; 2004 Nov; 88(1):1-8. PubMed ID: 15538040
[TBL] [Abstract][Full Text] [Related]
20. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
Mouridsen H; Gershanovich M; Sun Y; Pérez-Carrión R; Boni C; Monnier A; Apffelstaedt J; Smith R; Sleeboom HP; Jänicke F; Pluzanska A; Dank M; Becquart D; Bapsy PP; Salminen E; Snyder R; Lassus M; Verbeek JA; Staffler B; Chaudri-Ross HA; Dugan M
J Clin Oncol; 2001 May; 19(10):2596-606. PubMed ID: 11352951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
